GlaxoSmithKline (GSK), the British biopharma company, has announced a $30 billion investment in U.S. research and development (R&D) and manufacturing over the next five years. This announcement coincides with U.S. President Donald Trump"s second state visit to the United Kingdom.
The investment includes plans for a new factory in Pennsylvania, which will cost $1.2 billion. The initiative aims to enhance U.S. research, clinical trials, and supply chain infrastructure while creating thousands of jobs. This move comes amid ongoing tariff threats on pharmaceutical imports.
For more information on related coverage, see recent developments regarding President Trump"s visit.